Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

Jieqiong Liu; Ying Wang; Zhenluan Tian; Ying Lin; Hengyu Li; Zhaowen Zhu; Qiang Liu; Shicheng Su; Yinduo Zeng; Weijuan Jia; Yaping Yang; Shengqiang Xu; Herui Yao; Wen Jiang; Erwei Song

doi:10.1038/s41467-022-30569-0

Nature Communications (May 2022)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

Jieqiong Liu,
Ying Wang,
Zhenluan Tian,
Ying Lin,
Hengyu Li,
Zhaowen Zhu,
Qiang Liu,
Shicheng Su,
Yinduo Zeng,
Weijuan Jia,
Yaping Yang,
Shengqiang Xu,
Herui Yao,
Wen Jiang,
Erwei Song

Affiliations

Jieqiong Liu: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Ying Wang: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Zhenluan Tian: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Ying Lin: Department of Breast and Thyroid Surgery, First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University
Hengyu Li: Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University (Second Military Medical University)
Zhaowen Zhu: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Qiang Liu: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Shicheng Su: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Yinduo Zeng: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Weijuan Jia: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Yaping Yang: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Shengqiang Xu: YuceNeo, Shenzhen
Herui Yao: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Wen Jiang: Department of Radiation Oncology, MD Anderson Cancer Center
Erwei Song: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

DOI: https://doi.org/10.1038/s41467-022-30569-0
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Therapeutic options for patients with triple-negative breast cancer (TNBC) in later-line setting are limited. Here the authors report the results of a phase 2 clinical trial to evaluate efficacy and safety of the combination of camrelizumab (anti-PD1), apatinib (VEGFR2 inhibitor), and eribulin in patients with heavily pre-treated advanced TNBC.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal